Immitra Bio: Funding, Investors & Team (Sep 2026)
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommon diseases with significant unmet medical needs.
Immitra Bio has raised $3.1M across 2 funding rounds on record, the most recent a Pre-Seed of $3.0M announced in Jul 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immitra Bio Company Profile and Key Stats
Latest funding round on record: Jul 2026.
Immitra Bio Funding Rounds
Immitra Bio raised $190k in an undisclosed round announced in Jun 2026.
1 month later, a Pre-Seed of $3.0M was announced in Jul 2026.
Immitra Bio Investors
9 investors are recorded in total; the 5 named above are those the record identifies.
Immitra Bio Founders and Leadership Team
Contact details for the Immitra Bio team: 2 of 2 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Immitra Bio Funding Compared to Other Biotechnology Startups
Immitra Bio's latest round of $3.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immitra Bio in Biotechnology and Schlieren
Companies Similar to Immitra Bio
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Pharvaris is a clinical-stage company working on bringing a new oral bradykinin B2 receptor antagonist to…
Immitra Bio Funding FAQs
What does Immitra Bio do?
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommon diseases with significant unmet medical needs.
How much funding has Immitra Bio raised?
Immitra Bio has raised $3.1M across 2 rounds on record. The most recent is a Pre-Seed of $3.0M announced in Jul 2026.
When did Immitra Bio last raise funding?
Immitra Bio's most recent funding round on record is a Pre-Seed of $3.0M, announced in Jul 2026.
Who has invested in Immitra Bio?
Investors on record for Immitra Bio include Venture Kick, Zürcher Kantonal Bank, Kickfund, FONGIT, another.vc. FundedIQ records 9 investors in total.
Who founded Immitra Bio?
FundedIQ lists Amir Taheri-Ghahfarokhi (CSO and Co-founder), Jan Nelis (Founder) at Immitra Bio.
Where is Immitra Bio headquartered?
Immitra Bio is based in Schlieren, Zurich, Switzerland.
How many employees does Immitra Bio have?
Immitra Bio is in the 1-10 employee band.
When was Immitra Bio founded?
Immitra Bio was founded in 2024.
How does Immitra Bio's funding compare to other Biotechnology startups?
Immitra Bio's latest round of $3.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Immitra Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immitra Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.